Mymee is a leader in personalized trials and care for people with debilitating autoimmune rheumatic and long COVID symptoms. 

Our story begins with our founder, Mette Dyhrbeg, who struggled with several autoimmune diagnoses including psoriatic arthritis and Sjögren’s syndrome from the age of 14.  After testing the best drugs, Humira included, and hearing from experts “there is nothing more we can do”, Mette took matters into her own hands. As an entrepreneur and economist, she dedicated her time to analyzing her own data until she could identify triggers that correlated directly to her flares. 

Sixteen months later in 2012, she was able to bring herself into remission and realized that she could not stop with her own case. In 2013 she filed her first patent, now cited by companies like Apple, and began the journey to help others, leading to the founding of Mymee, Inc in 2017. 

Since then, Mymee's award winning personalized trial platform has been clinically validated, with over 1,000 personalized trials completed. 

In June 2020 Mymee expanded research and care to include Long COVID and in April 2022, Mymee acquired Breakthrough Health, creators of the #1 MS app Emilyn, extending its team and technology. 

So long as there is no cure or treatment that works for everyone, we believe individuals deserve access to the self-evidence-based personalized trials & care needed to take control of their disease.